Galapagos Updates on Cell Therapy Business Strategic Review

An announcement from Galapagos ( (GLPG) ) is now available.

On October 1, 2025, Galapagos NV announced an update on its strategic review of alternatives for its cell therapy business, initially disclosed on May 13, 2025. The company has received a limited number of non-binding offers from financial consortia interested in acquiring the business. Galapagos is working with these potential bidders to finalize due diligence and secure financing commitments. The deadline for binding offers is approaching, and a decision regarding the divestment or alternative actions is expected by November 5, 2025.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Spark’s Take on GLPG Stock

According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.

The overall stock score reflects significant financial challenges, particularly in cash flow and profitability, overshadowed by strong technical indicators suggesting positive market momentum. While the company has strategic plans to expand its pipeline and manufacturing, high restructuring costs and anticipated cash burn remain key concerns.

To see Spark’s full report on GLPG stock, click here.

More about Galapagos

Galapagos is a biotechnology company operating in Europe, the U.S., and Asia, focused on transforming patient outcomes through innovative science and technology. The company addresses high unmet medical needs and has a deep pipeline of best-in-class medicines, including a decentralized cell therapy manufacturing platform.

Average Trading Volume: 270,040

Technical Sentiment Signal: Hold

Current Market Cap: $2.24B

For an in-depth examination of GLPG stock, go to TipRanks’ Overview page.